GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (OTCPK:TRUMY) » Definitions » YoY Rev. per Sh. Growth

TRUMY (Terumo) YoY Rev. per Sh. Growth : 13.68% (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Terumo YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Terumo's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 was 13.68%.

Terumo's Revenue per Share for the three months ended in Sep. 2024 was $1.18.

Terumo YoY Rev. per Sh. Growth Historical Data

The historical data trend for Terumo's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo YoY Rev. per Sh. Growth Chart

Terumo Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.43 -3.29 5.04 4.26 0.32

Terumo Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.03 4.79 2.17 7.73 13.68

Terumo YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Terumo's YoY Rev. per Sh. Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Mar. 2024 )
=(Revenue per Share (A: Mar. 2024 )-Revenue per Share (A: Mar. 2023 ))/ | Revenue per Share (A: Mar. 2023 ) |
=(4.099-4.086)/ | 4.086 |
=0.32 %

Terumo's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2024 )
=(Revenue per Share (Q: Sep. 2024 )-Revenue per Share (Q: Sep. 2023 )) / | Revenue per Share (Q: Sep. 2023 )) |
=(1.18-1.038)/ | 1.038 |
=13.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Terumo YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Terumo's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Terumo Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (OTCPK:TRUMY) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
TSE:7733 TSE:6869 TSE:7747 TSE:7741 TSE:3360 TSE:7730 TSE:7716 TSE:8086 TSE:7780 TSE:7817 ISRG XPAR:EL BDX XSWX:ALC WST XSWX:STMN OCSE:COLO B RMD XPAR:DIM BAX
Traded in Other Exchanges
TRUMF:USA 4543:Mexico 4543:Japan TUO:Germany
Address
2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Website
https://www.terumo.com
Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.